The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma
Journal of Thoracic Oncology · 2023-12 · 18 (12) · 1689-1702
DOI: 10.1016/j.jtho.2023.08.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thoracic Oncology, 2023-12. Verfasst von Andrea S Wolf und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: andrea.wolf@mountsinai.org. Hauptthemen laut MEDLINE: Lung Neoplasms, Mesothelioma, Malignant, Mesothelioma, Pleural Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, AstraZeneca.
Abstract (Originalsprache)
INTRODUCTION: The International Association for the Study of Lung Cancer developed an international pleural mesothelioma database to improve staging. Data entered from 1995 to 2009 (training data set) were analyzed previously to evaluate supplemental prognostic factors. We evaluated these factors with new clinical data to determine whether the previous models could be improved. METHODS: Patients entered into the database from 2009 to 2019 (validation cohort) were assessed for the association between previous prognosticators and overall survival using Cox proportional hazards regression with bidirectional stepwise selection. Additional variables were analyzed and models were compared using Harrell's C-index. RESULTS: The training data set included 3101 patients and the validation cohort, 1733 patients. For the multivariable pathologic staging model applied to the training cohort, C-index was 0.68 (95% confidence interval [CI]: 0.656-0.705). For the validation data set (n = 497), C-index was 0.650 (95% CI: 0.614-0.685), and pathologic stage, histologic diagnosis, sex, adjuvant therapy, and platelet count were independently associated with survival. Adding anemia to the model increased the C-index to 0.652 (95% CI: 0.618-0.686). A basic presentation model including all parameters before staging yielded a C-index of 0.668 (95% CI: 0.641-0.695). In comparison, the European Organization for Research and Treatment of Cancer model yielded C-indices of 0.550 (95% CI: 0.511-0.589) and 0.577 (95% CI: 0.550-0.604) for pathologic staging and presentation models, respectively. CONCLUSIONS: Although significant predictors differed slightly, the International Association for the Study of Lung Cancer training model performed well in the validation set and better than the model of the European Organization for Research and Treatment of Cancer. International collaboration is critical to improve outcomes in this rare disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: andrea.wolf@mountsinai.org.
- Cancer Research and Biostatistics, Seattle, Washington.
- Medical School of the University of Western Australia, Crawley, Western Australia, Australia.
- Department of Thoracic Surgery, Guy's Hospital, London, United Kingdom.
- Division of Thoracic Surgery, Toronto General Hospital, Ontario, Canada.
- Section of Hematology/Oncology, University of Chicago, Chicago, Illinois.
Förderung
- NCI NIH HHS
- National Cancer Institute
- AstraZeneca
- National Institutes of Health
- International Association for the Study of Lung Cancer
Zitieren
APA
Wolf, A. S., Rosenthal, A., Giroux, D. J., Nowak, A. K., Bille, A., de Perrot, M., Kindler, H. L., Rice, D., Opitz, I., Rusch, V. W., Pass, H. I., Members of the International Association for the Study of Lung Cancer (IASLC) Staging and Prognostic Factors Committee, & Advisory Board, and Participating Institutions (2023). The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma. Journal of Thoracic Oncology, 18(12), 1689-1702. https://doi.org/10.1016/j.jtho.2023.08.005
Vancouver
Wolf AS, Rosenthal A, Giroux DJ, Nowak AK, Bille A, de Perrot M, et al. The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma. Journal of Thoracic Oncology. 2023;18(12):1689-1702. doi:10.1016/j.jtho.2023.08.005
BibTeX
@article{Wolf2023,
author = {Wolf, Andrea S and Rosenthal, Adam and Giroux, Dorothy J and Nowak, Anna K and Bille, Andrea and de Perrot, Marc and Kindler, Hedy L and Rice, David and Opitz, Isabelle and Rusch, Valerie W and Pass, Harvey I and Members of the International Association for the Study of Lung Cancer (IASLC) Staging and Prognostic Factors Committee, Members of the International Association for the Study of Lung Cancer (IASLC) Staging and Prognostic Factors Committee and Advisory Board, and Participating Institutions, Advisory Board, and Participating Institutions},
title = {The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma},
journal = {Journal of Thoracic Oncology},
year = {2023},
volume = {18},
number = {12},
pages = {1689--1702},
doi = {10.1016/j.jtho.2023.08.005}
}
EUVIMED